SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-18-008198
Filing Date
2018-04-16
Accepted
2018-04-16 07:00:32
Documents
4
Period of Report
2018-06-07
Effectiveness Date
2018-04-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A agle-def14a_20180607.htm DEF 14A 936219
2 GRAPHIC g2018041317110540711599.jpg GRAPHIC 3159
3 GRAPHIC g2018041317111168211600.jpg GRAPHIC 77855
4 GRAPHIC g2018041317111171211601.jpg GRAPHIC 71549
  Complete submission text file 0001564590-18-008198.txt   1147873
Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37722 | Film No.: 18755493
SIC: 2834 Pharmaceutical Preparations